Dr. Reddy''s Lab
Ticker > Company >

Dr. Reddy''s Lab share price

Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  255k   1k   188

1377.55
-11.80 (-0.85%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1391

Today's Low

₹ 1372.9

52 Week High

₹ 1420.2

52 Week Low

₹ 1104.69

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 114946.07 Cr.

Enterprise Value

₹ 114522.07 Cr.

No. of Shares

83.44 Cr.

P/E

23.9

P/B

4.27

Face Value

₹ 1

Div. Yield

0.58 %

Book Value (TTM)

₹  322.47

CASH

₹ 1216.9 Cr.

DEBT

₹ 792.9 Cr.

Promoter Holding

26.64 %

EPS (TTM)

₹  57.64

Sales Growth

14.86%

ROE

19.54 %

ROCE

25.52%

Profit Growth

66.18 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ

Index Presence

The company is present in 42 Indices.

NFT500MOQ50

Nifty500 Multicap Momentum Quality 50 index
45087.4
  -590.799999999996 (-1.29339597444732%)

NIFTY100WEIGHT

Nifty100 Equal Weight
31313.9
  -32.8999999999978 (-0.104954891727382%)

NIFTYEQWGT

NIFTY50 Equal Weight
29317.25
  -147.450000000001 (-0.500429327296736%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
27260.25
  -184.950000000001 (-0.673888330199823%)

NIFTY100

Nifty 100
24500.75
  -131.25 (-0.53284345566742%)

NIFTY

Nifty 50
23644.9
  -168.5 (-0.707584805193717%)

NIFTYLOWVOL

Nifty Low Volatility 50
23624
  -39.4000000000015 (-0.166501855185652%)

NIFTYPHARMA

Nifty Pharma
23241.15
  232.800000000003 (1.01180658326219%)

NFTALQVL30

NIFTY Alpha Quality Low-Volatility 30
22656.9
  -81.7999999999993 (-0.359739123168867%)

NIFTY500

Nifty 500
22357.15
  -88.0499999999993 (-0.392288774437288%)

NFTALQLV30

NIFTY Alpha Quality Value Low-Volatility 30
20400
  -98.9000000000015 (-0.482464912751424%)

NT100LOW30

Nifty100 Low Volatility 30
19187.2
  -72.5999999999985 (-0.376950954838573%)

NFTQTLO30

NIFTY Quality Low-Volatility 30
16888.45
  -32.2999999999993 (-0.190889883722645%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15763.75
  -52.2000000000007 (-0.330046566915054%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15704.55
  -26.75 (-0.170043162357847%)

NIFTYHEALTH

Nifty Healthcare Index
14893.65
  193.799999999999 (1.31838079980406%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14636.7
  -83.8999999999996 (-0.569949594445873%)

NFT500EQUAL

Nifty 500 Equal Weight
14134.85
  -50.3999999999996 (-0.35529863766941%)

NIFTYMFG

NIFTY India Manufacturing
13727.2
  -133.65 (-0.964226580620953%)

NIFTYV20

Nifty50 Value 20
13457.9
  -82.75 (-0.611122804296693%)

NIFTY200

Nifty 200
13408.85
  -50.8999999999996 (-0.378164527572944%)

NIFTYTOTALMCAP

NIFTY Total Market
12619.1
  -52.6999999999989 (-0.415884089079677%)

NIFTY100ESG

NIFTY100 ESG
4698.5
  -15.8000000000002 (-0.335150499543946%)

BSE HC

S&P Bse Healthcare
45166.88
  528.769999999997 (1.18457076251659%)

BSEINDEX

BSE Index
36459.78
  -286.050000000003 (-0.778455677827938%)

BSE500

S&P Bse 500
35178.37
  -113.049999999996 (-0.320332817438329%)

SS6535

BSE Sensex Sixty 65:35
32453.06
  -210.459999999999 (-0.644327371942766%)

SNSX60

BSE Sensex Sixty
32102.38
  -198.779999999999 (-0.615395855752543%)

BSE100

S&P Bse 100
25091.51
  -101.670000000002 (-0.403561598813651%)

SNSX50

S&P Bse Sensex50
24875.01
  -153.93 (-0.615008066662037%)

200EQW

BSE 200 Equal Weight
12632.38
  -5.07000000000153 (-0.0401188530914198%)

BSE200

S&P Bse 200
10938.83
  -37.3600000000006 (-0.340373116719017%)

ALLCAP

S&P Bse Allcap
10471.31
  71.0699999999997 (0.683349615008888%)

LMI250

S&P Bse 250 LargeMidCap
10386.97
  -33.1900000000005 (-0.318517182077827%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10304.57
  5.32999999999993 (0.051751391364796%)

LRGCAP

S&P Bse LargeCap
9198.26
  -41.1299999999992 (-0.445159258349292%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
8833.92
  -41.7399999999998 (-0.470274886599975%)

CARBONEX

S&P Bse Carbonex
4344.48
  15.7799999999997 (0.364543627417002%)

SPBSLVIP

S&P Bse Low Volatility
1755.76
  -4 (-0.227303723234984%)

S&PDIVSTABLE

S&P Bse Dividend Stability
984.64
  -2.71000000000004 (-0.274472071707099%)

MFG

S&P Bse Manufacturing
982.47
  -7.17999999999995 (-0.725509018339809%)

ESG100

S&P Bse 100 ESG Index
393.36
  -2.32999999999998 (-0.588844802749622%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.86%
3 Year13.43%
5 Year12.89%

Profit Growth

1 Year66.18%
3 Year25.7%
5 Year27.73%

ROE%

1 Year19.54%
3 Year14.12%
5 Year15.45%

ROCE %

1 Year25.52%
3 Year18.7%
5 Year18.5%

Debt/Equity

0.0329

Price to Cash Flow

33.32

Interest Cover Ratio

266.656

CFO/PAT (5 Yr. Avg.)

1.10892490932047

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 26.64 0.00
Jun 2024 26.65 0.00
Mar 2024 26.65 0.00
Dec 2023 26.65 0.00
Sep 2023 26.66 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 25.6955975183994% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 266.656.
  • The Company has been maintaining an effective average operating margins of 24.19728% in the last 5 years.
  • Company’s PEG ratio is 0.3622279421163.
  • The company has an efficient Cash Conversion Cycle of 18.7778 days.
  • Company has a healthy liquidity position with current ratio of 3.2145.
  • The company has a good cash flow management; CFO/PAT stands at 1.10892490932047.

 Limitations

  • The company has shown a poor revenue growth of 13.4331549527408% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 4838.7 4103 5104.8 5841.2 6696.3
Total Expenditure 3209.6 3446.7 3726.2 3888.2 3974.7
Operating Profit 1629.1 656.3 1378.6 1953 2721.6
Other Income 223.1 227.6 212.7 217.8 207.6
Interest 5.8 5.6 5.9 7.1 28.4
Depreciation 245.8 246.4 246.2 249.8 260
Exceptional Items 0 0 0 0 0
Profit Before Tax 1600.6 631.9 1339.2 1913.9 2640.8
Tax 408 156.7 304.4 496.7 758.7
Profit After Tax 1192.6 475.2 1034.8 1417.2 1882.1
Adjusted EPS (Rs) 14.3 5.7 12.41 16.99 4.51

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 11850.4 13349.1 14405.2 16962.5 19483.8
Total Expenditure 8980.8 10212.3 11811.1 12747.7 13557.4
Operating Profit 2869.6 3136.8 2594.1 4214.8 5926.4
Other Income 743.2 801.1 482 591.3 862.3
Interest 47.8 46.7 38 16.9 21.8
Depreciation 789.2 835 814.3 923.2 975.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 2775.8 3056.2 2223.8 3866 5791.3
Tax -161.9 869.8 600.6 1253.2 1449.3
Net Profit 2937.7 2186.4 1623.2 2612.8 4342
Adjusted EPS (Rs.) 35.35 26.28 19.51 31.37 52.06

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 83.1 83.2 83.2 83.3 83.4
Total Reserves 15108.8 16900.5 18253 20390.9 24157.4
Borrowings 19.3 17.7 19.7 28.6 49.5
Other N/C liabilities -528.8 -186.9 75.2 432.3 530.9
Current liabilities 4180.5 4560.3 6045.1 4439.7 5538.1
Total Liabilities 18862.9 21374.8 24476.2 25374.8 30359.3
Assets
Net Block 4433.9 5844.3 6150.5 7195.3 7589.1
Capital WIP 384.1 877.1 1186.4 899.1 1171.9
Intangible WIP 27.7 23.7 13.9 25.3 39.1
Investments 3367.1 3392.2 3018.7 3248.6 3216.3
Loans & Advances 542 293.2 409.8 324.6 507.2
Other N/C Assets 1.4 0.1 202.6 0 33.4
Current Assets 10106.7 10944.2 13494.3 13681.9 17802.3
Total Assets 18862.9 21374.8 24476.2 25374.8 30359.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2775.8 3056.2 2223.8 3866 5791.3
Adjustment 681.8 273.3 845.1 1045.8 602
Changes in Assets & Liabilities -1141.5 632.7 -1241.4 923.7 -1624.1
Tax Paid -476.9 -448 -488.8 -782.7 -1319.5
Operating Cash Flow 1839.2 3514.2 1338.7 5052.8 3449.7
Investing Cash Flow -1689.2 -1453.6 -1990.1 -3403.1 -3428.7
Financing Cash Flow -224.1 -794.3 505.5 -2696.9 68.1
Net Cash Flow -74.1 1266.3 -145.9 -1047.2 89.1

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 26.66 26.65 26.65 26.65 26.64
anuradha gunupati 0.01 0.01 0.01 0.01 0.01
g v prasad - - - 11.52 11.52
gunupati venkateswara pra... 1.52 1.52 1.52 1.52 1.52
kallam satish reddy huf 3.31 3.31 3.31 3.31 3.31
samrajyam reddy kallam 0.67 0.67 0.67 0.67 0.67
satish reddy kallam 0.54 0.54 0.54 9.61 9.60
aps trust 20.59 20.59 20.59 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 73.34 73.35 73.35 73.35 73.36
first sentier investors i... 2.32 2.32 2.32 2.32 2.32
hdfc trustee company ltd.... 1.75 1.81 1.62 1.75 1.34
icici prudential value di... - - - 1.17 2.09
investor education and pr... - - - 0.20 0.20
life insurance corporatio... 7.34 5.16 5.05 5.52 5.60
nippon life india trustee... - - - 1.02 1.33
nps trust-a/c sbi pension... 2.09 2.19 2.30 2.53 2.66
sbi nifty index fund - - - 1.29 1.49
mirae asset nifty india m... - - - 1.11 -
government of singapore 1.21 1.07 1.02 - -
investor education and pr... 0.14 0.20 0.20 - -
sbi-etf nifty 50 1.67 1.46 1.42 - -
hdfc life insurance compa... 1.04 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Reddy's Laboratories’ arm incorporates wholly-owned subsidiary in Finland 24 Dec, 10:13 AM Dr. Reddy’s Laboratories informs about allotment of equity shares 20 Dec, 10:04 AM Dr. Reddy’s Laboratories submits press release 28 Nov, 11:30 AM Dr. Reddy’s Laboratories launches Toripalimab in India 28 Nov, 10:14 AM Dr.Reddy's Laboratories informs about investor conference 26 Nov, 3:40 PM Dr.Reddy's Laboratories informs about analyst meet 26 Nov, 3:35 PM Dr. Reddy's Laboratories’ arm recalling Morphine Sulfate extended-release tablets 18 Nov, 10:50 AM Dr. Reddy’s Laboratories informs about disclosure 14 Nov, 10:34 AM Dr. Reddy's to invest up to Rs 600 crore in step-down wholly owned subsidiary 7 Nov, 10:27 AM Dr. Reddy's Laboratories reports 9% fall in Q2 consolidated net profit 6 Nov, 11:43 AM Dr. Reddy's Lab - Quaterly Results 5 Nov, 4:07 PM Dr. Reddy's Lab - Quaterly Results 5 Nov, 4:07 PM Dr. Reddy's Lab - Quaterly Results 5 Nov, 4:07 PM Dr. Reddy's Laboratories launches drug to treat chronic constipation 29 Oct, 11:10 AM Dr. Reddy’s Laboratories informs about incorporation of step down wholly-owned subsidiary 5 Oct, 1:08 PM Dr. Reddy's Laboratories’ arm incorporates new wholly-owned subsidiary 5 Oct, 1:01 PM Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences 3 Oct, 9:38 AM Dr. Reddy's makes investment of $620 million in DRL SA 28 Sep, 2:50 PM Dr. Reddy’s Laboratories informs about disclosure 26 Sep, 9:48 AM USFDA completes GMP inspection at Dr. Reddy's Laboratories’ R&D centre 20 Sep, 6:10 PM Dr. Reddy’s Laboratories informs about disclosure 20 Sep, 5:36 PM Dr. Reddy's gets EIR for API manufacturing facility in Andhra Pradesh 6 Sep, 10:42 AM Dr. Reddy’s Laboratories informs about update 6 Sep, 10:20 AM Dr. Reddy's Laboratories’ arm recalling Ibuprofen tablets in multiple strengths in US market 5 Sep, 12:30 PM USFDA completes Pre-Approval Inspection at Dr. Reddy’s Srikakulam formulations manufacturing facility 24 Aug, 11:49 AM Dr. Reddy’s Laboratories informs about update on inspection 12 Aug, 9:54 AM Dr. Reddy's Laboratories gets EIR for formulations manufacturing facilities in Visakhapatnam 12 Aug, 9:30 AM Dr. Reddy's Laboratories’ arm makes investment in Clean Renewable Energy KK 2A 2 Aug, 9:47 AM Dr. Reddy’s Laboratories to infuse fund in Switzerland subsidiary 29 Jul, 11:07 AM Dr. Reddy's Laboratories reports marginal fall in Q1 consolidated net profit 29 Jul, 10:14 AM Dr. Reddy’s Laboratories informs about press release 29 Jul, 9:42 AM Dr. Reddy's Lab - Quaterly Results 27 Jul, 4:12 PM Dr. Reddy's Lab - Quaterly Results 27 Jul, 4:12 PM Dr. Reddy's Lab - Quaterly Results 27 Jul, 4:12 PM Dr. Reddy's Laboratories’ arm enters into definitive agreement with Haleon plc 27 Jun, 11:28 AM Dr. Reddy’s Laboratories informs about disclosure 27 Jun, 9:53 AM Dr. Reddy's Laboratories’ arm, Ingenus Pharmaceuticals enter into license agreement 13 Jun, 10:13 AM Dr Reddy's Laboratories submits analyst meet intimation 10 Jun, 12:44 PM USFDA completes GMP inspection at Dr. Reddy's API manufacturing facility in Andhra Pradesh 8 Jun, 1:00 PM Dr. Reddy's Laboratories’ Aurigene inaugurates biologics facility in Hyderabad 4 Jun, 9:37 AM Dr. Reddy's Laboratories’ step down arm inks distribution agreement with Novartis Pharma 27 May, 4:44 PM Dr. Reddy's makes investment of Rs 650 crore in Aurigene Oncology 25 May, 4:16 PM Dr. Reddy’s Laboratories informs about disclosure 24 May, 12:14 PM Dr. Reddy's Laboratories’ arm recalling Javygtor Powder for Oral Solution in US 21 May, 11:10 AM Dr. Reddy’s Laboratories informs about audio recordings of earnings call 8 May, 10:31 AM Dr. Reddy's Laboratories reports 36% rise in Q4 consolidated net profit 7 May, 4:52 PM Dr. Reddy's Lab - Quaterly Results 7 May, 4:10 PM Dr. Reddy's Lab - Quaterly Results 7 May, 4:10 PM Dr. Reddy's Lab - Quaterly Results 7 May, 4:10 PM Dr. Reddy's Laboratories launches Doxycycline Capsules 3 May, 5:40 PM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time. Dr. Reddy''s Lab stock price today is Rs 1376.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dr. Reddy''s Lab cash from the operating activity was Rs 3449.7 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.0329 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was 65.9827 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 30.4170644330162 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a average ROE of 19.5418 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dr. Reddy''s Lab is Rs 1376.9. One can use valuation calculators of ticker to know if Dr. Reddy''s Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Dr. Reddy''s Lab

Dr. Reddy''s Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Dr. Reddy's Laboratories Ltd. is a leading Indian pharmaceutical company specializing in the production of generic drugs and active pharmaceutical ingredients. In this article, we will provide a comprehensive analysis of Dr. Reddy's Laboratories Ltd.'s stock from a long-term investor's perspective. We will cover various topics such as the company's share price, balance sheet, annual report, dividend, quarterly results, stock price trends, price charts, latest news, conference call (concall) insights, transcripts, investor presentations, promoters, and shareholders.

Dr. Reddy's Laboratories Ltd., a prominent Indian pharmaceutical company, focuses on producing generic drugs and active pharmaceutical ingredients. This article offers a thorough analysis of Dr. Reddy's Laboratories Ltd.'s stock, tailored for long-term investors. We will delve into the share price trends, balance sheet, annual reports, dividends, quarterly results, stock price movements, price charts, latest news, concall insights, transcripts, investor presentations, promoters, and shareholders to provide a holistic view of the company's financial health and growth prospects.

Dr. Reddy''s Laboratories Ltd. Share Price:

Dr. Reddy's Laboratories Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s share price and identify any trends or patterns. The company's share price has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. Balance Sheet:

Dr. Reddy's Laboratories Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and inventory, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s balance sheet and identify any red flags. The company's balance sheet has been strong over the past few years, reflecting the company's ability to generate cash and manage its liabilities. 

Dr. Reddy's Lab Reserves  

Total reserves of Dr. Reddy’s Lab as on March 2024 can be computed as ?24,157.40 crores which has doubled from ?15,108.80 crores as on March 2020. This steady growth may be understood through the sound financial health of the company and its maintaining capacity of the earning over the years.

Dr. Reddy's Lab Debt  

Outstanding borrowings have increased significantly from ? 19.30 crores in the previous year that is in the March-2020 to ? 49.50 crores in the present March-2024. This would mean that there is an increased debt leverage, but one needs to also look at how well this debt is used to finance operations.

Dr. Reddy's Lab Assets  

Total assets of Dr. Reddy’s Lab increased from March 2020- ?18,862.90 crores to March 2024 – ?30,359.30 crores. Total operating assets increased significantly from ? 10, 106.70 crores to ? 17,802.30 crores – signifying a better position of working capital and operational utilisation.

Dr. Reddy’s Lab Current Liabilities  

Total amount of current liabilities also rose from ?4,180.50 crores as on 31 march 2020 to ?5,538.10 crores as on 31 march 2024. It may mean an increase in business activities and the necessity of additional working capital.

In this work, Dr. Reddy’s Lab balance sheet for the given period is analyzed in the form of the company’s standalone balance sheet, which underlines the company’s solvency. It is also important for investors to look at stock screeners to get a clue about growth prospects within the pharmaceutical industry.

Dr. Reddy''s Laboratories Ltd. Annual Report:

Dr. Reddy's Laboratories Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Dr. Reddy's Laboratories Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Dividend:

Dr. Reddy's Laboratories Ltd. pays dividends to its shareholders. The company has a consistent dividend policy and pays dividends regularly. Long-term investors should consider this when evaluating Dr. Reddy's Laboratories Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Dr. Reddy''s Laboratories Ltd. Quarterly Results:

Dr. Reddy's Laboratories Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Dr. Reddy''s Laboratories Ltd. Stock Price:

The stock price of Dr. Reddy's Laboratories Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Dr. Reddy's Laboratories Ltd.'s stock price and identify potential buying opportunities. The stock price of Dr. Reddy's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Dr. Reddy's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. News:

Keeping up to date with the latest news about Dr. Reddy's Laboratories Ltd. is important for investors. Our website provides the latest news about Dr. Reddy's Laboratories Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Dr. Reddy''s Laboratories Ltd. Concall:

Dr. Reddy's Laboratories Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Dr. Reddy's Laboratories Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Dr. Reddy''s Laboratories Ltd. Transcripts:

Transcripts of Dr. Reddy's Laboratories Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Investor Presentations:

Dr. Reddy's Laboratories Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Dr. Reddy's Laboratories Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Dr. Reddy's Laboratories Ltd.'s promoters include Dr. Reddy's family and entities related to them. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Dr. Reddy's Laboratories Ltd. are relatively stable, which is a positive sign for long-term investors.

Dr. Reddy''s Laboratories Ltd. Shareholders:

Dr. Reddy's Laboratories Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Dr. Reddy's Laboratories Ltd. is diverse, which is a positive sign for long-term investors.

Dr. Reddy''s Laboratories Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Dr. Reddy's Laboratories Limited ROCE

The Return on Capital Employed (ROCE) for Dr. Reddy's Laboratories Limited can be found in the financials table above. This ratio helps in assessing how efficiently the company is utilizing its capital to generate profits. A higher ROCE indicates efficient capital allocation and better profitability.

Dr. Reddy's Laboratories Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) figure for Dr. Reddy's Laboratories Limited is available for reference in the above financials table. EBITDA provides insight into the company's operational performance without the impact of certain accounting factors like interest and taxes.

Dr. Reddy's Laboratories Limited DPS

Dividends Per Share (DPS) data can be found in the financials section of this page. DPS represents the amount of dividends each shareholder receives per share owned. It is an important metric for investors looking for steady income from their investments.

Dr. Reddy's Laboratories Limited EPS

Earnings Per Share (EPS) for Dr. Reddy's Laboratories Limited is provided in the financials section above. EPS indicates the company's profitability on a per-share basis, giving investors an idea of the company's earning power and performance relative to its outstanding shares.

Performance Revenue Analysis of Dr. Reddy’s Lab 

The quarterly and annual figures are; Net Sales (In Rs crore): Quarter ended September 2024 (Q2 FY 25) = 6,696.30, YoY up by 38% from Quarter ended September 2023 (Q2FY24) = 4,838.70. In sequence, the revenue was up by 14.6% from Rs 5,841.20 crore IPO spline of the prior quarter ended in June 2024, indicating the sales were on a strong footing.

Analyzing the Operating Profit of Dr. Reddy’s Lab company

Operating profit for Q2 FY25 zoomed to Rs 2,721.60 crore up by 67% from Rs 1,629.10 crore in Q2 FY24. Operating profit at Rs 2,708 crore was up 39% from Rs 1,953 crore in Q1 FY25 and shows operational superiority and better margins.

The following report shows the head, Dr. Reddy’s lab profit after tax

The PAT also improved significantly to Rs 1,882.10 crore in September’ 2024. This is up 57.8 percent from Rs 1,192.60 crore in Q2 FY24 and 32.8 percent from Rs 1,417.20 crore in the June 2024 first quarter. This quarter’s outflow through tax was Rs 758.70 crore.

Dr. Reddy's Lab EPS 

Similarly, the adjustment of EPS for Q2 FY25 was at Rs 4.51 which declined from Rs 14.30 from the corresponding period of last year and from Rs 16.99 from Q1 FY 25. Such a decline might be caused by an adjustment or dilution factor.

It is possible to gain some understanding of Dr. Reddy’s Labs Standalone Quarterly Results for the Quarter Ended on 30th September 2024 and a good direction of the financials. Self-assembled tools for sectors and stocks as well as constant scrutiny of sectors can assist investors capture pertinent growth opportunities such as those in the healthcare Industry.

Read More
X